Celon Pharma FCF per Share
The Free Cash Flow per Share of Celon Pharma (CLN.WA) as of Oct 22, 2026 is -0.57 PLN. In the previous year, Free Cash Flow per Share was -0.70 PLN — a change of -18.85% (higher).
Get this data via API
Financial Data API
FCF per Share
-0.57PLN
YoY
-18.85%
Last updated:
The Celon Pharma FCF per Share history
3 Years
10 Years
25 Years
Max
| YEAR | FCF per Share | YoY |
|---|---|---|
| -0.57PLN | -18.85% | |
| -0.70PLN | -12.63% | |
| -0.80PLN | +5.84% | |
| -0.76PLN | -1,281.48% | |
| 0.06PLN | -110.20% | |
| -0.63PLN | -59.63% | |
| -1.56PLN | +78.49% | |
| -0.87PLN | +549.58% | |
| -0.13PLN | +841.67% | |
| -0.01PLN | -105.69% | |
| 0.25PLN | +644.65% | |
| 0.03PLN | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Celon Pharma Stock analysis
Frequently Asked Questions about Celon Pharma stock
Free Cash Flow per Share of Celon Pharma is -0.57 PLN in 2025.
Free Cash Flow per Share of Celon Pharma changed from -0.70 PLN to -0.57 PLN, representing a -18.85% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Free Cash Flow per Share Celon Pharma since 2006 – with annual values, charts, and detailed analysis.
FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Cash Flow — Celon Pharma
All Key Metrics — Celon Pharma
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth